Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Application of bergapten in preparation of drugs for treating colorectal cancer

A technology of bergamot lactone, colorectal cancer, applied in the field of medicine

Inactive Publication Date: 2020-05-08
东莞市滨海湾中心医院 +1
View PDF1 Cites 2 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0003] At present, the single-drug effective rate of 5-Fu is only 12%, the single-drug effective rate of L-OHP is 12%, and the single-drug effective rate of Irinotecan is 18%, which means that CRC patients are resistant to chemotherapy drugs

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of bergapten in preparation of drugs for treating colorectal cancer
  • Application of bergapten in preparation of drugs for treating colorectal cancer
  • Application of bergapten in preparation of drugs for treating colorectal cancer

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0025] Example 1 Detection of cell drug resistance

[0026] 1×10 3 A SW1116, LoVo, SW1116 / 5-Fu and LoVo / 5-Fu cells were seeded in a 96-well plate at 37°C, 5% CO 2 After 48 hours of culture in an incubator with saturated humidity; different concentrations of bergamot lactone (0 μmol / L, 1 μmol / L, 10 μmol / L and 100 μmol / L) were applied to the above cells for 48 hours; then SW1116 and LoVo cells were treated with DMEM complete medium with different concentrations of 5-Fu (0mg / L, 1mg / L, 2mg / L, 4mg / L and 8mg / L) was continuously cultured for 48h, and SW1116 / 5-Fu and LoVo / 5-Fu cells were cultured with different Concentration of 5-Fu (0mg / L, 10mg / L, 20mg / L, 40mg / L and 80mg / L) of DMEM complete culture solution continued to culture for 48h. Then use CCK-8 kit and microplate reader to detect the best absorbance value at 450nm, and calculate IC50 value to evaluate cell drug resistance.

[0027] GraphpadPrism 5.0 software was used for statistical analysis, IC50 value was calculated by no...

Embodiment 2

[0031] Example 2 Western blot detection

[0032] 1×10 5 A SW1116 / 5-Fu and LoVo / 5-Fu cells were seeded in a 6-well plate at 37°C, 5% CO 2, after 24 hours of culture in an incubator with saturated humidity, different concentrations of bergamot lactone (1 μmol / L, 10 μmol / L and 100 μmol / L) were applied to the above cells for 48 hours, washed with PBS, added an appropriate amount of RIPA lysate, and placed in After lysing on ice, the total protein was extracted and the protein concentration was determined using the BCA protein concentration detection kit. 10% SDS-PAGE gel electrophoresis (120V, 1h) was used to separate proteins, PVDF membrane was transferred (90V, 2h), and 10% skim milk was blocked for 1h. Then, Bcl-2(1:200), Bax(1:200), EBI3(1:200), STAT3(1:100), p-STAT3(1:100), CYPIB1(1:200) and MEKK2 (1:200) was incubated overnight on a shaker, with β-actin as an internal reference. After washing with TBST, horseradish peroxidase-labeled secondary antibody (Goat Anti Mouse I...

Embodiment 3

[0036] Example 3 Effect of bergamotide combined with EBI3 blocking peptide on drug resistance of CRC cells

[0037] 1×10 3 A SW1116, LoVo, SW1116 / 5-Fu and LoVo / 5-Fu cells were seeded in a 96-well plate at 37°C, 5% CO 2 , cultured in an incubator with saturated humidity for 48 hours, then divided into groups: the control group was cultured only with DMEM complete medium; the EBI3 Bp group was cultured with DMEM complete medium containing 1 μg / mL EBI3 blocking peptide; the Bg group was cultured with 10 μmol / L Bergamot lactone was cultured in DMEM complete medium; Bg combined with EBI3 Bp group was cultured in DMEM complete medium containing 1 μg / mL EBI3 blocking peptide and 10 μmol / L bergamot lactone. Then SW1116 and LoVo cells were continuously cultured with DMEM complete medium with different concentrations of 5-Fu (0mg / L, 1mg / L, 2mg / L, 4mg / L and 8mg / L) for 48h, and SW1116 / 5-Fu and LoVo / 5-Fu cells were continuously cultured with DMEM complete medium with different concentra...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses application of bergapten in preparation of drugs for treating colorectal cancer and belongs to the technical field of medicines. According to the application of the bergapten in the preparation of the drugs for treating the colorectal cancer, disclosed by the invention, through administrating the bergapten of different concentrations to SW1116, LoVo, SW1116 / 5-Fu and LoVo / 5-Fu of the human colorectal cancer for intervention, drug resistance of the bergapten to human colorectal cancer cells 5-Fu and influence on EBI3 / STAT3 signal channels are observed, and thus, an experiment basis is provided for the bergapten in treatment of a liver cancer as an antitumor drug.

Description

technical field [0001] The invention relates to the technical field of medicine, and more specifically relates to the application of bergamot lactone in the preparation of medicines for treating colorectal cancer. Background technique [0002] In recent years, the morbidity and mortality of colorectal cancer (CRC) have been on the rise, especially nearly a quarter of patients have metastases at the time of first diagnosis, and half of them eventually develop into unresectable metastases. For these patients, chemotherapy based on 5-fluorouracil (5-Fu), oxaliplatin (L-OHP) and irinotecan (Irinotecan) is the main treatment. [0003] At present, the single-drug effective rate of 5-Fu is only 12%, the single-drug effective rate of L-OHP is 12%, and the single-drug effective rate of Irinotecan is 18%, which means that CRC patients are resistant to chemotherapy drugs. For a long time, our research team has been engaged in the study of drug resistance and immunopathological mechani...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/37A61K38/02A61P35/00
CPCA61K31/37A61K38/02A61P35/00A61K2300/00
Inventor 梁艳芳曾今诚林碧华叶子瑜陈灿
Owner 东莞市滨海湾中心医院
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com